Abstract Number: 1650 • 2014 ACR/ARHP Annual Meeting
Prevalence and Prognostic Implications of IgG4 in Membranous Lupus Nephritis
Background/Purpose: Patients with membranous lupus nephritis (MLN) have increased risk of thrombosis and different prognosis than other classes of lupus nephritis (LN). Previous studies demonstrated…Abstract Number: 867 • 2014 ACR/ARHP Annual Meeting
Specific SLE Disease Manifestations in the Six Months Prior to Conception Predict Similar Manifestations during Pregnancy
Background/Purpose: Active SLE, in particular lupus nephritis, during the six months prior to conception is associated with disease flare during pregnancy. Previous studies, however, have…Abstract Number: 657 • 2014 ACR/ARHP Annual Meeting
Distinct Contributions of C1q and C3 in Preventing Immunogenicity of Apoptotic Cells in Lupus
Background/Purpose: Defective clearance of apoptotic cells (AC) and complement deficiency are important contributors to the pathogenesis of systemic lupus. Dead (sunburn) cells and complement…Abstract Number: 2737 • 2014 ACR/ARHP Annual Meeting
Microrna-155 Suppresses IL-21 Signaling and Production in Systemic Lupus Erythematosus
Background/Purpose IL-21 is a key regulator of B cells functions and autoantibody production and is mainly produced by follicular T helper cells. The purpose of…Abstract Number: 2109 • 2014 ACR/ARHP Annual Meeting
Are Patient Ratings of Providers and Health Plans Associated with Technical Quality of Care in SLE?
Background/Purpose . Prior research has shown that the technical quality of SLE care is associated with the degree of subsequent accumulated damage. However, it is…Abstract Number: 1647 • 2014 ACR/ARHP Annual Meeting
Relationship Between Apom/S1P Levels and Atherosclerosis in Women with Systemic Lupus Erythematosus
Background/Purpose: SLE patients are at risk for atherosclerotic cardiovascular disease (ASCVD). In some SLE patients, high density lipoprotein (HDL) has impaired vasoprotective effects, and this…Abstract Number: 865 • 2014 ACR/ARHP Annual Meeting
Cardiovascular Events Prior to or Early after Diagnosis of SLE
Background/Purpose: A large multicenter multinational inception cohort was established to study risk factors for atherosclerosis (AS) in SLE. Previous studies have shown a history of…Abstract Number: 651 • 2014 ACR/ARHP Annual Meeting
Inhibiting Tweak (TNF-like weak inducer of apoptosis) Signaling Improves Blood Brain Barrier Integrity and Protects from Neuronal Damage in Murine Neuropsychiatric Lupus
Background/Purpose: While neuropsychiatric involvement in systemic lupus erythematosus (NPSLE) is relatively common and appears early, the underlying mechanisms are not fully understood. The disruption of…Abstract Number: 2722 • 2014 ACR/ARHP Annual Meeting
Rapamycin Corrects GATA-3 Deficiency in Lupus Treg
Background/Purpose: As demonstrated by the negative correlation between Treg frequency or suppressive function and SLE disease activity index score, it is tempting to speculate that…Abstract Number: 2112 • 2014 ACR/ARHP Annual Meeting
Patterns of Medication Use Before, During, and After Pregnancy Among Women with Systematic Lupus Erythematosus: A Population-Based Study
Background/Purpose: Systemic lupus erythematosus (SLE) disproportionately affects women during childbearing years. Given the limited data on perinatal medication use among patients, our objective was…Abstract Number: 1632 • 2014 ACR/ARHP Annual Meeting
Is Liopxin A4 a Biomarker for Systemic Lupus Erythematosus?
Background/Purpose : Systemic lupus erythematosus (SLE) is characterized by autoantibody production and immune complex deposition which trigger both a local and systemic inflammatory response. The…Abstract Number: 859 • 2014 ACR/ARHP Annual Meeting
TGF-β3-Producing CD4+CD25–LAG3+ Regulatory T Cells Control B Cell Responses
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibody production and associated with a wide range of clinical manifestations. Recent case-control association…Abstract Number: 636 • 2014 ACR/ARHP Annual Meeting
Liposomal-Glucocorticoids: A Novel Approach to the Therapy of SLE
Background/Purpose Glucocorticoids (GCs) have been known for years to be the most effective therapy in SLE. Their use is however limited by the need of…Abstract Number: 2696 • 2014 ACR/ARHP Annual Meeting
Relationship Between Soluble sCD23 and B Cell Activation Factor in Patients with Systemic Lupus Erythematosus before and after Rituximab
Background/Purpose CD23 is the low-affinity receptor for IgE (FceRII). The soluble form, sCD23 is released into the circulation and in vitro this is consistent with…Abstract Number: 2049 • 2014 ACR/ARHP Annual Meeting
Fatigue Is a Risk Factor for Subsequent Functional Decline in SLE
Background/Purpose: In geriatrics, fatigue has been shown to be a harbinger of future functional decline. Fatigue is associated with poor function in systemic lupus erythematosus…
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- …
- 38
- Next Page »